{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:11:03Z","timestamp":1772165463447,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1111658"],"award-info":[{"award-number":["OPP1111658"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"crossref","award":["262686"],"award-info":[{"award-number":["262686"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"name":"JPI-EC-AMR","award":["271176\/H10"],"award-info":[{"award-number":["271176\/H10"]}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The publication fund of UiT The Arctic University of Norway"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As antibiotic resistance creates a significant global health threat, we need not only to accelerate the development of novel antibiotics but also to develop better treatment strategies using existing drugs to improve their efficacy and prevent the selection of further resistance. We require new tools to rationally design dosing regimens from data collected in early phases of antibiotic and dosing development. Mathematical models such as mechanistic pharmacodynamic drug-target binding explain mechanistic details of how the given drug concentration affects its targeted bacteria. However, there are no available tools in the literature that allow non-quantitative scientists to develop computational models to simulate antibiotic-target binding and its effects on bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this work, we have devised an extension of a mechanistic binding-kinetic model to incorporate clinical drug concentration data. Based on the extended model, we develop a novel and interactive web-based tool that allows non-quantitative scientists to create and visualize their own computational models of bacterial antibiotic target-binding based on their considered drugs and bacteria. We also demonstrate how Rifampicin affects bacterial populations of Tuberculosis bacteria using our vCOMBAT tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The vCOMBAT online tool is publicly available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/combat-bacteria.org\/\">https:\/\/combat-bacteria.org\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12859-021-04536-3","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T06:02:44Z","timestamp":1641448964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-6434","authenticated-orcid":false,"given":"Vi Ngoc-Nha","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan","family":"Ascioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"Martinecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Clarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Mostowy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Abel zur Wiesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"4536_CR1","unstructured":"Nations U. 2020. http:\/\/www.un.org\/pga\/71\/event-latest\/high-level-meeting-on-antimicrobial-resistance\/."},{"issue":"7502","key":"4536_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/509555a","volume":"509","author":"M Woolhouse","year":"2014","unstructured":"Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature. 2014;509(7502):555\u20137. https:\/\/doi.org\/10.1038\/509555a.","journal-title":"Nature."},{"issue":"9","key":"4536_CR3","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, Du Bois J, Venter A, Phillips PPJ, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, Van Soolingen D, Van Ingen J, Magis-Escurra C, Burger D, Van Balen GP, Aarnoutse RE. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058\u201365. https:\/\/doi.org\/10.1164\/rccm.201407-1264OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4536_CR4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.2.e19","author":"AJ Lan","year":"2000","unstructured":"Lan AJ, Colford JM, Colford JM. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. Pediatrics. 2000. https:\/\/doi.org\/10.1542\/peds.105.2.e19.","journal-title":"Pediatrics"},{"issue":"12","key":"4536_CR5","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1128\/AAC.40.12.2765","volume":"40","author":"JJ Roord","year":"1996","unstructured":"Roord JJ, Wolf BH, Gossens MM, Kimpen JL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother. 1996;40(12):2765\u20138. https:\/\/doi.org\/10.1128\/AAC.40.12.2765.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4536_CR6","first-page":"560","volume":"8","author":"AV Deun","year":"2004","unstructured":"Deun AV, Salim MAH, Kumar Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh A standardised approach may provide a reasonable alternative to individualised treatment of MDR-TB in resource-poor settings. However, DOTS- plus programmes in resource-p. Int J Tuberc Lung Dis. 2004;8(5):560\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4536_CR7","unstructured":"WHO: The Shorter MDR-TB Regimen. http:\/\/www.who.int\/tb\/Short_MDR_regimen_factsheet.pdf?ua=1"},{"issue":"22","key":"4536_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1056\/NEJMra1413919","volume":"373","author":"CR Horsburgh","year":"2015","unstructured":"Horsburgh CR, Barry CE, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373(22):2149\u201360. https:\/\/doi.org\/10.1056\/NEJMra1413919.","journal-title":"N Engl J Med"},{"key":"4536_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002487","author":"P Ankomah","year":"2012","unstructured":"Ankomah P, Levin BR. Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012. https:\/\/doi.org\/10.1371\/journal.ppat.1002487.","journal-title":"PLoS Pathog"},{"issue":"6050","key":"4536_CR10","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1126\/science.1208747","volume":"333","author":"Q Zhang","year":"2011","unstructured":"Zhang Q, Lambert G, Liao D, Kim H, Robin K, Tung C-K, Pourmand N, Austin RH. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science. 2011;333(6050):1764\u20137. https:\/\/doi.org\/10.1126\/science.1208747.","journal-title":"Science"},{"issue":"5562","key":"4536_CR11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1126\/science.1063814","volume":"295","author":"C Dye","year":"2002","unstructured":"Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world\u2019s slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002;295(5562):2042\u20136. https:\/\/doi.org\/10.1126\/science.1063814.","journal-title":"Science"},{"key":"4536_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)01283-1","author":"SR Norrby","year":"2005","unstructured":"Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Eur Soc Clin Microbiol Infect Dis (ESCMID). 2005. https:\/\/doi.org\/10.1016\/S1473-3099(05)01283-1.","journal-title":"Eur Soc Clin Microbiol Infect Dis (ESCMID)"},{"issue":"7","key":"4536_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002851","volume":"16","author":"G Davies","year":"2019","unstructured":"Davies G, Boeree M, Hermann D, Hoelscher M. Accelerating the transition of new tuberculosis drug combinations from phase ii to phase iii trials: new technologies and innovative designs. PLoS Med. 2019;16(7):1\u201310. https:\/\/doi.org\/10.1371\/journal.pmed.1002851.","journal-title":"PLoS Med"},{"key":"4536_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nchembio.1795","volume":"11","author":"R Zhang","year":"2015","unstructured":"Zhang R. Pharmacodynamics which trails are your drugs taking? Nat Chem Biol. 2015;11:382\u20133.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"4536_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002769","volume":"16","author":"C Lienhardt","year":"2019","unstructured":"Lienhardt C, Nahid P. Advances in clinical trial design for development of new tb treatments: a call for innovation. PLoS Med. 2019;16(3):1\u20135. https:\/\/doi.org\/10.1371\/journal.pmed.1002769.","journal-title":"PLoS Med"},{"issue":"3","key":"4536_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00018-019-03376-y","volume":"77","author":"F Clarelli","year":"2020","unstructured":"Clarelli F, Liang J, Martinecz A, Heiland I, Abel zur Wiesch P. Multi-scale modeling of drug binding kinetics to predict drug efficacy. Cell Mol Life Sci. 2020;77(3):381\u201394. https:\/\/doi.org\/10.1007\/s00018-019-03376-y.","journal-title":"Cell Mol Life Sci"},{"issue":"287","key":"4536_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaa8760","volume":"7","author":"P Abel Zur Wiesch","year":"2015","unstructured":"Abel Zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelst\u00e4dter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Classic reaction kinetics can explain complex patterns of antibiotic action. Sci Transl Med. 2015;7(287):1\u201312. https:\/\/doi.org\/10.1126\/scitranslmed.aaa8760.","journal-title":"Sci Transl Med"},{"key":"4536_CR18","doi-asserted-by":"crossref","unstructured":"Clarelli F, Palmer A, Singh B, Storflor M, Lauksund S, Cohen T. Abel S, PAzW. Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLoS Comput Biol. 2020.","DOI":"10.1371\/journal.pcbi.1008106"},{"key":"4536_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2019.103937","volume":"74","author":"M Grobbelaar","year":"2019","unstructured":"Grobbelaar M, Louw GE, Sampson SL, Helden PD, Donald PR, Warren RM. Evolution of rifampicin treatment for tuberculosis. Infect Genet Evol. 2019;74: 103937. https:\/\/doi.org\/10.1016\/j.meegid.2019.103937.","journal-title":"Infect Genet Evol"},{"issue":"1","key":"4536_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39\u201349. https:\/\/doi.org\/10.1016\/S1473-3099(16)30274-2.","journal-title":"Lancet Infect Dis"},{"key":"4536_CR21","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014."},{"key":"4536_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jedc.2015.05.009","volume":"58","author":"SB Aruoba","year":"2015","unstructured":"Aruoba SB, Fern\u00e1ndez-Villaverde J. A comparison of programming languages in economics. J Econ Dyn Control. 2015;58:265\u201373. https:\/\/doi.org\/10.1016\/j.jedc.2015.05.009.","journal-title":"J Econ Dyn Control"},{"key":"4536_CR23","unstructured":"Galassi M. GNU scientific library reference manual. 2018. https:\/\/www.gnu.org\/software\/gsl\/."},{"issue":"1","key":"4536_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00529-6","volume":"7","author":"G Aljayyoussi","year":"2017","unstructured":"Aljayyoussi G, Jenkins VA, Sharma R, Ardrey A, Donnellan S, Ward SA, Biagini GA. Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Nat Sci Rep. 2017;7(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-017-00529-6.","journal-title":"Nat Sci Rep"},{"issue":"4","key":"4536_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002773","volume":"16","author":"N Strydom","year":"2019","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim TS, Barry CE, Zimmerman M, Dartois V, Savic RM. Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16(4):1\u201326. https:\/\/doi.org\/10.1371\/journal.pmed.1002773.","journal-title":"PLoS Med"},{"issue":"7","key":"4536_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002842","volume":"16","author":"KE Dooley","year":"2019","unstructured":"Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM. Advancing the development of new tuberculosis treatment regimens: the essential role of translational and clinical pharmacology and microbiology. PLoS Med. 2019;16(7):1\u201314. https:\/\/doi.org\/10.1371\/journal.pmed.1002842.","journal-title":"PLoS Med"},{"issue":"9","key":"4536_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/cid\/cir184","volume":"52","author":"J Van Ingen","year":"2011","unstructured":"Van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52(9):194\u20139. https:\/\/doi.org\/10.1093\/cid\/cir184.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4536_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1004749","volume":"12","author":"D Cadosch","year":"2016","unstructured":"Cadosch D, Abel zur Wiesch P, Kouyos R, Bonhoeffer S. The role of adherence and retreatment in de novo emergence of MDR-TB. PLoS Comput Biol. 2016;12(3):1\u201319. https:\/\/doi.org\/10.1371\/journal.pcbi.1004749.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"4536_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1005321","volume":"13","author":"P Abel zur Wiesch","year":"2017","unstructured":"Abel zur Wiesch P, Clarelli F, Cohen T. Using chemical reaction kinetics to predict optimal antibiotic treatment strategies. PLoS Comput Biol. 2017;13(1):1\u201328. https:\/\/doi.org\/10.1371\/journal.pcbi.1005321.","journal-title":"PLoS Comput Biol"},{"key":"4536_CR30","first-page":"325","volume":"330","author":"W Wehrli","year":"1977","unstructured":"Wehrli W. Kinetic Studies of the Interaction between Rifampicin and DNA-Dependent RNA Polymerase of Escherichia coli. Biol Res. 1977;330:325\u201330.","journal-title":"Biol Res"},{"key":"4536_CR31","unstructured":"COMPOUND SUMMARY of Rifampicin. (2019). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Rifampicin Accessed 01 Apr 2020."}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-021-04536-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T06:03:44Z","timestamp":1641449024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-021-04536-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4536"],"URL":"https:\/\/doi.org\/10.1186\/s12859-021-04536-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.05.236711","asserted-by":"object"}]},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}